CN Patent

CN112313214A — 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法

Assigned to Merck Patent GmbH · Expires 2021-02-02 · 5y expired

What this patent protects

本发明涉及用作BTK抑制剂的1‑(4‑{[6‑氨基‑5‑(4‑苯氧基‑苯基)‑嘧啶‑4‑基氨基]‑甲基}‑4‑氟代‑哌啶‑1‑基)‑丙烯酮(化合物I)或其药学上可接受的盐的固体形式。

USPTO Abstract

本发明涉及用作BTK抑制剂的1‑(4‑{[6‑氨基‑5‑(4‑苯氧基‑苯基)‑嘧啶‑4‑基氨基]‑甲基}‑4‑氟代‑哌啶‑1‑基)‑丙烯酮(化合物I)或其药学上可接受的盐的固体形式。

Drugs covered by this patent

Patent Metadata

Patent number
CN112313214A
Jurisdiction
CN
Classification
—
Expires
2021-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.